Is Galectin Therapeutics Inc (NASDAQ:GALT) a Buy? The Stock Reported more Sellers

July 27, 2018 - By Jason Dias

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 1.86 in Q1 2018. Its up 1.33, from 0.53 in 2017Q4. It increased, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Morgan Stanley accumulated 44,260 shares. Wells Fargo & Mn accumulated 10,582 shares. Bluecrest Capital Limited accumulated 101,406 shares. Neuberger Berman Group Limited Co holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 82,494 shares. Northern Corporation invested in 0% or 79,256 shares. Stratos Wealth Partners Limited has 28,154 shares. Barclays Pcl owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 20,123 shares. Moreover, Financial Bank Of America De has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 8,260 shares. Sabby Mngmt Limited Liability Corp holds 0.08% or 143,400 shares. California Pub Employees Retirement System owns 23,450 shares. Benchmark Cap Advsrs has 221,700 shares for 0.83% of their portfolio. Lpl Financial Limited Liability Company reported 23,593 shares. State Street invested in 17,450 shares or 0% of the stock. Pnc Fincl Group Incorporated invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Blackrock owns 196,157 shares.

Since February 1, 2018, it had 3 insider purchases, and 22 selling transactions for $14.40 million activity. On Thursday, February 1 the insider FREEMAN KEVIN D bought $8,191. $409,997 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by TRABER PETER G on Friday, June 8. Shlevin Harold H. sold $671,988 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, June 8. Shares for $1.49 million were sold by 10X Fund – L.P.. CALLICUTT JACK W also sold $65,167 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, June 13. On Friday, June 1 the insider CZIRR JAMES C sold $256,081.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.57% in short interest. GALT’s total short interest was 2.57M shares in July as published by FINRA. Its up 2.57% from 2.51 million shares, reported previously. With 456,200 shares average volume, it will take short sellers 6 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 9.1%.

The stock decreased 1.46% or $0.08 during the last trading session, reaching $5.4. About 193,039 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since July 27, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $203.80 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs” on July 22, 2018. Also Fool.com published the news titled: “3 Stocks That Could Double Your Money” on July 26, 2018. Seekingalpha.com‘s news article titled: “Galectin Therapeutics IPF Patent Solidifies Platform Technology Status” with publication date: July 05, 2018 was also an interesting one.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.